Page last updated: 2024-08-25

atovaquone and Disease Models, Animal

atovaquone has been researched along with Disease Models, Animal in 29 studies

Research

Studies (29)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	9 (31.03)	18.2507
2000's	5 (17.24)	29.6817
2010's	11 (37.93)	24.3611
2020's	4 (13.79)	2.80

Authors

Authors	Studies
Bathurst, I; Buckner, FS; Burrows, J; Charman, SA; Charman, WN; Creason, S; Deng, X; El Mazouni, F; Floyd, DM; Gujjar, R; Matthews, D; Phillips, MA; Rathod, PK; Shackleford, DM; White, J; White, KL	1
Bane, CE; Black, C; Butler, K; Caridha, D; Cooper, RA; Dodean, RA; Gaona, H; Gaynor-Ohnstad, L; Huezo, SJ; Kancharla, P; Kelly, JX; Kreishman-Deitrick, M; Leed, SE; Li, Q; Li, Y; Lin, H; Luong, TL; Marcsisin, S; Melendez, V; Nolan, C; Olmeda, R; Potter, B; Pou, S; Rasmussen, SA; Read, L; Riscoe, MK; Roncal, N; Sciotti, RJ; Smilkstein, MJ; Sousa, J; Stephens, MT; Tan, JC; Vesely, B; Vuong, C; Winter, RW; Xie, L; Zeng, Q; Zhang, J; Zhang, P	1
Bane, CE; Bayles, BR; Black, C; Butler, K; Caridha, D; Ceja, FG; Cooper, RA; Dodean, RA; Gaona, H; Gaynor-Ohnstad, L; Kancharla, P; Kelly, JX; Kreishman-Deitrick, M; Leed, SE; Li, Q; Li, Y; Lin, H; Luong, TL; Marcsisin, S; Melendez, V; Mu, J; Nolan, C; Olmeda, R; Potter, B; Pou, S; Pybus, B; Rasmussen, SA; Read, L; Reynolds, KA; Riscoe, MK; Roncal, N; Rosenthal, PJ; Sciotti, RJ; Smilkstein, MJ; Sousa, J; Tumwebaze, PK; Vesely, B; Vuong, C; Xie, L; Zeng, Q; Zhang, J; Zhang, P	1
Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV	1
Asakawa, AH; Brockmeyer, F; Casandra, D; Huang, L; Kyle, DE; LaCrue, AN; Maher, SP; Maignan, JR; Manetsch, R; Mashkouri, S; Monastyrskyi, A; Padin-Irizarry, V; Parvatkar, PT; Sakhno, YI; Zhao, Y	1
Ball, ZT; Frank, DA; Gaikwad, AS; Hamada, Y; Heppler, LN; Horton, TM; Jiang, K; Krueger, MJ; Long, X; Mangubat-Medina, AE; Munoz, JO; Narayanan, P; Oyadomari, S; Rashid, R; Redell, MS; Seashore, EL; Stevens, AM; Sumazin, P; Terrell, MC; Tošić, I; Walker, SR; Xiang, M	1
Adeojo, LW; Alfaro, R; Ashbaugh, A; Cushion, MT; Kovacs, JA; Kumar, P; Lu, R; Mannino, R; Tramont, E	1
Betz, W; Bial, J; Billman, Z; Camargo, N; Campo, B; Charman, SA; Chuenchob, V; Fishbaugher, M; Flannery, EL; Foquet, L; Kappe, SH; Lee, J; Mikolajczak, SA; Murphy, SC; Navarro, MJ; Nguyen, T; Olsen, TM; Phillips, MA; Sack, BK; Saunders, J; Schafer, C; Wilson, EM	1
Bakshi, RP; Ippolito, MM; Mlambo, G; Nenortas, E; Owen, A; Rannard, SP; Savage, AC; Shapiro, TA; Tatham, LM; Tripathi, AK	1
Clark, HL; de Jesus, T; Ghannoum, MG; Minns, MS; Pearlman, E; Sun, Y	1
Berman, J; DiTusa, C; Gettayacamin, M; Im-erbsin, R; Kozar, MP; Ohrt, C; Pybus, B; Sousa, J; Tungtaeng, A	1
Büyükbaba Boral, O; Kaşali, K; Sönmez, N; Tekeli, F	1
Anahtar, M; Bar-Natan, M; Blonquist, T; Bradner, JE; Frank, DA; Giaccone, ZT; Heppler, LN; Hetz, C; Ho, VT; Jones, N; Kim, H; Kroll, Y; Liu, S; Marineau, JJ; Neuberg, D; Shaw, D; Soiffer, RJ; Stone, RM; Toniolo, PA; Walker, SR; Xiang, M; Ye, DQ	1
Borner, K; Fitzner, R; Heimesaat, MM; Lachenmaier, S; Liesenfeld, O; Lohman, U; Mauludin, R; Mueller, RH; Shubar, HM	1
Oz, HS; Tobin, T	1
Weiss, LM	1
Bobić, B; Djurković-Djaković, O; Grujić, J; Milenković, V; Nikolić, A	1
Aleksić, A; Bobić, B; Djurković-Djaković, O; Klun, I; Nikolić, A	1
Chollet, J; Santo-Tomas, J; Scheurer, C; Snyder, C; Wittlin, S	1
Hughes, WT; Killmar, JT; Oz, HS	1
Lederman, J; Rosenbaum, GS; Tanowitz, HB; Weiss, LM; Wittner, M	1
Araujo, FG; Remington, JS; Suzuki, Y	1
Gray, JS; Pudney, M	1
Yeo, AE	1
Gormley, PD; Lightman, S; Minnasian, D; Pavesio, CE	1
Aumjaud, Y; Derouin, F; Fessi, H; Sordet, F	1
Dalimi, A; Moshkani, SK	1
Angelici, E; Canipari, R; Contini, C	1
Araujo, FG	1

Reviews

1 review(s) available for atovaquone and Disease Models, Animal

Article	Year
Babesiosis in humans: a treatment review. Expert opinion on pharmacotherapy, 2002, Volume: 3, Issue:8 Topics: Animals; Anti-Bacterial Agents; Atovaquone; Azithromycin; Babesia microti; Babesiosis; Clindamycin; Disease Models, Animal; Drug Administration Schedule; Drug Therapy, Combination; Humans; Naphthoquinones; Randomized Controlled Trials as Topic	2002

Other Studies

28 other study(ies) available for atovaquone and Disease Models, Animal

Article	Year
Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice. Journal of medicinal chemistry, 2011, Jun-09, Volume: 54, Issue:11 Topics: Animals; Antimalarials; Dihydroorotate Dehydrogenase; Disease Models, Animal; Drug Design; Drug Discovery; Enzyme Inhibitors; Humans; Malaria; Mice; Microsomes, Liver; Molecular Structure; Oxidoreductases Acting on CH-CH Group Donors; Plasmodium berghei; Plasmodium falciparum; Protein Binding; Pyrimidines; Solubility; Structure-Activity Relationship; Triazoles	2011
Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials. Journal of medicinal chemistry, 2019, 04-11, Volume: 62, Issue:7 Topics: Acridones; Animals; Antimalarials; Disease Models, Animal; Drug Discovery; Hep G2 Cells; Humans; Malaria; Mice; Plasmodium; Species Specificity; Structure-Activity Relationship	2019
Lead Optimization of Second-Generation Acridones as Broad-Spectrum Antimalarials. Journal of medicinal chemistry, 2020, 06-11, Volume: 63, Issue:11 Topics: Acridones; Administration, Oral; Animals; Antimalarials; Cell Survival; Disease Models, Animal; Female; Half-Life; Hep G2 Cells; Humans; Life Cycle Stages; Malaria; Male; Mice; Mice, Inbred C57BL; Plasmodium falciparum; Structure-Activity Relationship	2020
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. Proceedings of the National Academy of Sciences of the United States of America, 2020, 12-08, Volume: 117, Issue:49 Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection	2020
Aminoalkoxycarbonyloxymethyl Ether Prodrugs with a pH-Triggered Release Mechanism: A Case Study Improving the Solubility, Bioavailability, and Efficacy of Antimalarial 4(1 Journal of medicinal chemistry, 2021, 05-27, Volume: 64, Issue:10 Topics: Administration, Oral; Animals; Antimalarials; Cyclization; Disease Models, Animal; Ethers; Female; Half-Life; Hydrogen-Ion Concentration; Malaria; Mice; Mice, Inbred BALB C; Plasmodium falciparum; Prodrugs; Quinolones; Solubility; Structure-Activity Relationship	2021
Atovaquone is active against AML by upregulating the integrated stress pathway and suppressing oxidative phosphorylation. Blood advances, 2019, 12-23, Volume: 3, Issue:24 Topics: Activating Transcription Factor 4; Adolescent; Animals; Apoptosis; Atovaquone; Cell Line, Tumor; Cell Survival; Child; Child, Preschool; Disease Models, Animal; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Mice; Mice, Knockout; Oxidative Phosphorylation; Signal Transduction; Xenograft Model Antitumor Assays	2019
A Novel Encochleated Formulation Improves Atovaquone Activity in a Murine Model of Pneumocystis Pneumonia. The Journal of infectious diseases, 2021, 07-15, Volume: 224, Issue:2 Topics: Anidulafungin; Animals; Antifungal Agents; Atovaquone; Disease Models, Animal; Mice; Pneumonia, Pneumocystis	2021
Assessing drug efficacy against Plasmodium falciparum liver stages in vivo. JCI insight, 2018, 01-11, Volume: 3, Issue:1 Topics: Animals; Antimalarials; Atovaquone; Disease Models, Animal; Drug Combinations; Drug Evaluation, Preclinical; Liver; Malaria, Falciparum; Mice; Plasmodium falciparum; Proguanil; Pyrimidines; Triazoles	2018
Long-acting injectable atovaquone nanomedicines for malaria prophylaxis. Nature communications, 2018, 01-22, Volume: 9, Issue:1 Topics: Animals; Anopheles; Antimalarials; Atovaquone; Chemoprevention; Disease Models, Animal; Drug Carriers; Drug Resistance; Female; Humans; Malaria; Male; Mice; Mice, Inbred C57BL; Nanoparticles; Plasmodium berghei; Theranostic Nanomedicine	2018
Atovaquone Impairs Growth of Aspergillus and Fusarium Keratitis Isolates by Modulating Mitochondrial Function and Zinc Homeostasis. Investigative ophthalmology & visual science, 2018, 03-01, Volume: 59, Issue:3 Topics: Animals; Antifungal Agents; Aspergillus; Atovaquone; Disease Models, Animal; Epithelial Cells; Eye Infections, Fungal; Fusarium; Homeostasis; Hyphae; Keratitis; Mice; Mice, Inbred C57BL; Mitochondria; Zinc	2018
Causal prophylactic efficacy of primaquine, tafenoquine, and atovaquone-proguanil against Plasmodium cynomolgi in a rhesus monkey model. The Journal of parasitology, 2014, Volume: 100, Issue:5 Topics: Aminoquinolines; Animals; Antimalarials; Atovaquone; Disease Models, Animal; Drug Combinations; Macaca mulatta; Malaria; Parasitemia; Plasmodium cynomolgi; Primaquine; Proguanil	2014
[Effects of atovaquone and astragalus combination on the treatment and IL-2, IL-12, IFN-γ levels on mouse models of acute toxoplasmosis]. Mikrobiyoloji bulteni, 2014, Volume: 48, Issue:4 Topics: Animals; Antiprotozoal Agents; Ascitic Fluid; Astragalus propinquus; Atovaquone; Disease Models, Animal; Drug Therapy, Combination; Female; Interferon-gamma; Interleukin-12; Interleukin-2; Mice; Mice, Inbred BALB C; Plant Extracts; Plant Roots; Toxoplasmosis, Animal	2014
Gene expression-based discovery of atovaquone as a STAT3 inhibitor and anticancer agent. Blood, 2016, 10-06, Volume: 128, Issue:14 Topics: Animals; Antineoplastic Agents; Apoptosis; Atovaquone; Cell Line, Tumor; Cell Membrane; Cell Survival; Cytokine Receptor gp130; Disease Models, Animal; Down-Regulation; Drug Discovery; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; Mice; Phosphorylation; Phosphotyrosine; STAT3 Transcription Factor; Treatment Outcome	2016
SDS-coated atovaquone nanosuspensions show improved therapeutic efficacy against experimental acquired and reactivated toxoplasmosis by improving passage of gastrointestinal and blood-brain barriers. Journal of drug targeting, 2011, Volume: 19, Issue:2 Topics: Administration, Oral; Animals; Antiprotozoal Agents; Atovaquone; Biological Availability; Brain; Chromatography, High Pressure Liquid; Disease Models, Animal; Excipients; Mice; Nanoparticles; Poloxamer; Sodium Dodecyl Sulfate; Suspensions; Tissue Distribution; Toxoplasma; Toxoplasmosis, Animal; Toxoplasmosis, Cerebral	2011
Atovaquone ameliorate gastrointestinal toxoplasmosis complications in a pregnancy model. Medical science monitor : international medical journal of experimental and clinical research, 2012, Volume: 18, Issue:9 Topics: Analysis of Variance; Animals; Anti-Infective Agents; Atovaquone; Disease Models, Animal; Female; Gastrointestinal Tract; Hepatitis; Hyperalgesia; Immunohistochemistry; Mice; Pancreatitis; Pregnancy; Toxoplasmosis, Congenital	2012
Efficacy of atovaquone combined with clindamycin against murine infection with a cystogenic (Me49) strain of Toxoplasma gondii. The Journal of antimicrobial chemotherapy, 2002, Volume: 50, Issue:6 Topics: Acute Disease; Animals; Atovaquone; Brain; Clindamycin; Cysts; Disease Models, Animal; Drug Therapy, Combination; Female; Mice; Naphthoquinones; Toxoplasma; Toxoplasmosis, Animal	2002
Stage conversion of Toxoplasma gondii RH parasites in mice by treatment with atovaquone and pyrrolidine dithiocarbamate. Microbes and infection, 2005, Volume: 7, Issue:1 Topics: Animals; Antiprotozoal Agents; Atovaquone; Brain; Disease Models, Animal; Drug Administration Schedule; Drug Therapy, Combination; Female; Mice; Naphthoquinones; Oocysts; Pyrrolidines; Thiocarbamates; Toxoplasma; Toxoplasmosis	2005
In vitro and in vivo interaction of synthetic peroxide RBx11160 (OZ277) with piperaquine in Plasmodium models. Experimental parasitology, 2007, Volume: 115, Issue:3 Topics: Animals; Antimalarials; Artemether; Artemisinins; Atovaquone; Disease Models, Animal; Drug Interactions; Drug Therapy, Combination; Erythrocytes; Female; Heterocyclic Compounds, 1-Ring; Humans; Malaria; Mice; Parasitemia; Parasitic Sensitivity Tests; Peroxides; Plasmodium berghei; Plasmodium falciparum; Pyrimethamine; Quinolines; Spiro Compounds	2007
Relative potency of 10 drugs with anti-Pneumocystis carinii activity in an animal model. The Journal of infectious diseases, 1994, Volume: 170, Issue:4 Topics: Animals; Anti-Infective Agents; Atovaquone; Azithromycin; Clarithromycin; Clindamycin; Clinical Trials as Topic; Dapsone; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Therapy, Combination; Humans; Naphthoquinones; Pentamidine; Pneumocystis Infections; Proguanil; Pyrimethamine; Rats; Sulfadoxine; Sulfamethoxazole; Trimethoprim; Trimethoprim, Sulfamethoxazole Drug Combination	1994
Atovaquone in the treatment of Babesia microti infections in hamsters. The American journal of tropical medicine and hygiene, 1996, Volume: 55, Issue:2 Topics: Animals; Anti-Bacterial Agents; Antimalarials; Antiprotozoal Agents; Artemisinins; Atovaquone; Azithromycin; Babesiosis; Cricetinae; Disease Models, Animal; Drug Therapy, Combination; Naphthoquinones; Parasitemia; Recurrence; Sesquiterpenes	1996
Use of rifabutin in combination with atovaquone, clindamycin, pyrimethamine, or sulfadiazine for treatment of toxoplasmic encephalitis in mice. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 1996, Volume: 15, Issue:5 Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antiprotozoal Agents; Atovaquone; Brain; Clindamycin; Disease Models, Animal; Drug Therapy, Combination; Encephalitis; Female; Mice; Mice, Inbred CBA; Naphthoquinones; Pyrimethamine; Rifabutin; Sulfadiazine; Toxoplasmosis, Cerebral; Treatment Outcome	1996
Therapeutic efficacy of atovaquone against the bovine intraerythrocytic parasite, Babesia divergens. The Journal of parasitology, 1997, Volume: 83, Issue:2 Topics: Acute Disease; Animals; Antiprotozoal Agents; Atovaquone; Babesia; Babesiosis; Cattle; Cells, Cultured; Disease Models, Animal; Dose-Response Relationship, Drug; Erythrocytes; Gerbillinae; Hemoglobinuria; Humans; Naphthoquinones; Parasitemia; Regression Analysis	1997
Direct comparison of antimalarial activity among PS-15 combination therapies by bioassay of serum samples from treated Saimiri sciureus. The Journal of parasitology, 1997, Volume: 83, Issue:3 Topics: Animals; Antimalarials; Atovaquone; Biological Assay; Dapsone; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Humans; Malaria, Falciparum; Naphthoquinones; Proguanil; Regression Analysis; Saimiri; Sulfamethoxazole	1997
Effects of drug therapy on Toxoplasma cysts in an animal model of acute and chronic disease. Investigative ophthalmology & visual science, 1998, Volume: 39, Issue:7 Topics: Acute Disease; Animals; Anti-Bacterial Agents; Antiprotozoal Agents; Atovaquone; Brain; Chorioretinitis; Chronic Disease; Cricetinae; Disease Models, Animal; Drug Therapy, Combination; Female; Mesocricetus; Naphthoquinones; Retina; Toxoplasma; Toxoplasmosis, Cerebral; Toxoplasmosis, Ocular	1998
Assessment of the activity of atovaquone-loaded nanocapsules in the treatment of acute and chronic murine toxoplasmosis. Parasite (Paris, France), 1998, Volume: 5, Issue:3 Topics: Acute Disease; Administration, Oral; Animals; Antiprotozoal Agents; Atovaquone; Brain; Capsules; Chronic Disease; Colloids; Disease Models, Animal; Drug Carriers; Drug Stability; Female; Lung; Mice; Naphthoquinones; Parasitemia; Solubility; Survival Rate; Suspensions; Temperature; Toxoplasma; Toxoplasmosis, Animal	1998
Evaluation of the efficacy of atovaquone alone or in combination with azithromycin against acute murine toxoplasmosis. Veterinary research communications, 2000, Volume: 24, Issue:3 Topics: Animals; Anti-Bacterial Agents; Antiprotozoal Agents; Atovaquone; Azithromycin; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Female; Mice; Naphthoquinones; Random Allocation; Toxoplasma; Toxoplasmosis, Animal	2000
Structural changes in rat Pneumocystis carinii surface antigens after terbinafine administration in experimental P. carinii pneumonia. The Journal of antimicrobial chemotherapy, 1999, Volume: 43, Issue:2 Topics: Animals; Antifungal Agents; Antigens, Fungal; Atovaquone; Blood; Blotting, Western; Bronchoalveolar Lavage Fluid; Disease Models, Animal; Electrophoresis; Immunosuppression Therapy; Male; Naphthalenes; Naphthoquinones; Pneumocystis; Pneumonia, Pneumocystis; Rats; Rats, Sprague-Dawley; Survival Rate; Terbinafine; Trimethoprim, Sulfamethoxazole Drug Combination	1999
Depletion of CD4+ T cells but not inhibition of the protective activity of IFN-gamma prevents cure of toxoplasmosis mediated by drug therapy in mice. Journal of immunology (Baltimore, Md. : 1950), 1992, Nov-01, Volume: 149, Issue:9 Topics: Animals; Antibodies, Protozoan; Antiprotozoal Agents; Atovaquone; CD4-Positive T-Lymphocytes; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Female; Hypersensitivity, Delayed; Immunity, Cellular; Interferon-gamma; Lymphocyte Depletion; Mice; Naphthoquinones; Toxoplasmosis, Animal; Treatment Failure	1992